New gel could ease blistering for skin disorder patients
NCT ID NCT07027345
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a gel called TolaSure on people aged 4 and older with epidermolysis bullosa simplex, a condition that causes fragile skin and blisters. For the first 2 months, some participants get the gel and others get a placebo; then everyone gets the gel for another 2 months. The goal is to see if the gel reduces blistering and pain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TolaSure gel (5% w/w)
What this could lead to
If successful, this gel could reduce blistering and pain for people with epidermolysis bullosa simplex, offering a new topical treatment option.
What could go wrong
This is a small Phase II trial with only 40 participants, so results may not apply to everyone. The gel may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA SIMPLEX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NU Dermatolgy CTU
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University School of Medicine, Dermatology Department
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.